{"nctId":"NCT00976456","briefTitle":"Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer","startDateStruct":{"date":"2009-09"},"conditions":["Non-squamous Non-small Cell Lung Cancer"],"count":271,"armGroups":[{"label":"Bevacizumab + Pemetrexed","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Bevacizumab + Pemetrexed"]},{"label":"Bevacizumab + Pemetrexed + Carboplatin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Bevacizumab + Pemetrexed + Carboplatin"]}],"interventions":[{"name":"Bevacizumab + Pemetrexed","otherNames":["Avastin®","ALIMTA®"]},{"name":"Bevacizumab + Pemetrexed + Carboplatin","otherNames":["Avastin®","ALIMTA®","Carboplatin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Stage IIIb and IV NSCLC, excluded squamous cell NSCLC\n* Age ≥ 65 years\n* ECOG 0-2\n\nExclusion Criteria:\n\n* Mixed, non-small cell and small cell tumours or mixed adenosquamous carcinomas with a predominant squamous component\n* History of haemoptysis\n* Evidence of tumour invading major blood vessels on imaging\n* Radiotherapy within 28 days prior to enrolment\n* Patients who are unable to interrupt aspirin or other nonsteroidal anti-inflammatory agents, other than an aspirin dose ≤ 1.3 grams per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam)\n* Current or recent (within 10 days of first dose of bevacizumab) use of full-dose oral or parenteral anticoagulants or thrombolytic agent for therapeutic purposes. Prophylactic use of anticoagulants is allowed\n* Clinically significant (i.e. active) cardiovascular disease for example CVA (≤6 months before enrolment), myocardial infarction (≤6 months before enrolment), unstable angina, CHF NYHA Class ≥II, serious cardiac arrhythmia requiring medication during the study and might interfere with regularity of the study treatment, or not controlled by medication\n* Non-healing wound, active peptic ulcer or bone fracture\n* History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of enrolment","healthyVolunteers":false,"sex":"ALL","minimumAge":"65 Years","stdAges":["OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival","description":"Progression free survival (defined as the number of days from the day of the first treatment until day of death (from any cause) or progression, whichever occurs earlier, or until the day of the last response assessment, if no progression or death (from any cause) is observed during the study).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":null},{"groupId":"OG001","value":"6.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival (defined as the number of days from the day of first treatment to death (from any cause), or until the last day if we know that the patient is alive).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","spread":null},{"groupId":"OG001","value":"14.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":119},"commonTop":["anaemia"]}}}